- Home
- NAT vs GOSS Comparison
NAT vs GOSS Comparison
Compare NAT & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAT
- GOSS
- Stock Information
- Founded
- NAT 1995
- GOSS 2015
- Country
- NAT Bermuda
- GOSS United States
- Employees
- NAT N/A
- GOSS N/A
- Industry
- NAT Marine Transportation
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- NAT Consumer Discretionary
- GOSS Health Care
- Exchange
- NAT Nasdaq
- GOSS Nasdaq
- Market Cap
- NAT 669.1M
- GOSS 585.9M
- IPO Year
- NAT 1997
- GOSS 2019
- Fundamental
- Price
- NAT $3.54
- GOSS $2.31
- Analyst Decision
- NAT Hold
- GOSS Strong Buy
- Analyst Count
- NAT 1
- GOSS 6
- Target Price
- NAT $3.00
- GOSS $8.60
- AVG Volume (30 Days)
- NAT 3.0M
- GOSS 3.6M
- Earning Date
- NAT 11-28-2025
- GOSS 11-06-2025
- Dividend Yield
- NAT 9.77%
- GOSS N/A
- EPS Growth
- NAT N/A
- GOSS N/A
- EPS
- NAT 0.06
- GOSS N/A
- Revenue
- NAT $301,169,000.00
- GOSS $40,237,000.00
- Revenue This Year
- NAT N/A
- GOSS N/A
- Revenue Next Year
- NAT $38.51
- GOSS $34.10
- P/E Ratio
- NAT $56.98
- GOSS N/A
- Revenue Growth
- NAT N/A
- GOSS N/A
- 52 Week Low
- NAT $2.13
- GOSS $0.66
- 52 Week High
- NAT $3.60
- GOSS $3.60
- Technical
- Relative Strength Index (RSI)
- NAT 65.83
- GOSS 43.52
- Support Level
- NAT $3.10
- GOSS $2.18
- Resistance Level
- NAT $3.35
- GOSS $2.61
- Average True Range (ATR)
- NAT 0.11
- GOSS 0.17
- MACD
- NAT 0.02
- GOSS -0.04
- Stochastic Oscillator
- NAT 88.78
- GOSS 24.22
About NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.